Table 3.
Included and evaluated but rejected parameter–covariate relationships
| Included parameter–covariate relationships | ||
|---|---|---|
| Relationship | ΔOFV | ΔBOV |
| Fed/fasted dosing on MTT | −90.4 | −29.2% |
| TB treatment on F | −65.4 | −3.8% |
| TB treatment with BSV on F | −84.6 | −9.8% |
| Evaluated but not included parameter–covariate relationships | ||
|---|---|---|
| Parameter | Covariates | |
| CL | age, sex, CD4 count, day/night, TB treatment, AL treatment, WHO-stage | |
| V | age, sex, CD4 count | |
| MTT | TB treatment, AL treatment, day/night | |
| F | AL treatment, fed/fasted dosing | |
Included relationships are listed together with the drop in OFV and the change in between occasion variability when comparing the final model with a model without the specified relationship. Abbreviations: AL, artemether/lumefantrine; ΔBOV, difference in between subject variability; BSV, between subject variability; CL, clearance; F, bioavailability, MTT, mean transit time; ΔOFV, difference in objective function value; TB, tuberculosis; V, volume of distribution.